Table 1 Patients’ characteristics and immunohistochemistry staining.

From: Activation of CD44/PAK1/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer

 

No. of cases

IHC-pAKT

IHC-CD44

Negative/weak

Strong

p

Negative/weak

Strong

p

Sex

 Male

153

109 (71%)

44 (29%)

0.5445

85 (56%)

67 (44%)

0.3504

 Female

30

23 (77%)

7 (23%)

15 (47%)

17 (53%)

Age

 ≤60

49

36 (73%)

13 (27%)

0.8071

22 (45%)

27 (55%)

0.121

 >60

134

96 (72%)

38 (28%)

78 (58%)

57 (42%)

Degree of diffr.

 I + II

138

99 (72%)

39 (28%)

0.8359

69 (50%)

70 (50%)

0.0315

 III

45

33 (73%)

12 (27%)

30 (68%)

14 (32%)

LN metastasis

 No

108

72 (67%)

36 (33%)

0.0479

61 (60%)

40 (40%)

0.0711

 Yes

75

60 (80%)

15 (20%)

33 (46%)

38 (54%)

Clinical stage

 I + II

132

94 (76%)

29 (24%)

0.0637

69 (53%)

62 (47%)

0.5388

 III + IV

51

38 (63%)

22 (37%)

30 (58%)

22 (42%)

Resection status

 R0

168

119 (71%)

49 (29%)

0.19

89 (54%)

77 (46%)

0.6814

 R1 + 2

15

13 (87%)

2 (13%)

10 (59%)

7 (41%)

IHC-pAKT1

 Negative/weak

132

   

78

48

0.0012

 Strong

51

   

17

32

IHC-CD44

 Negative/weak

100

78

17

0.0012

   

 Strong

84

48

32

   

FISH-FGFR1

 Negative

105

68

37

0.1564

46

57

0.2559

 Positive

32

25

7

19

15

IHC-FGFR1

 Negative/weak

109

81

28

0.1142

61

71

<0.0001

 Strong

50

31

19

25

3

  1. Bold values represent significant p-value  <  0.05.
  2. p values were calculated with the chi-squared test; significant values are indicated in bold type.
  3. ­diffr. differentiation, LN lymph node.
Back to article page